Related Party Transactions |
3 Months Ended |
|---|---|
Mar. 31, 2026 | |
| Related Party Transactions [Abstract] | |
| Related Party Transactions | 12. Related Party Transactions Effective December 20, 2024, Kirk Ways, M.D., a member of the board of the directors, began serving as the Company’s interim Chief Medical Officer pursuant to a consulting agreement. During the three months ended March 31, 2026 and 2025, the Company recognized compensation expense of $0.3 million and $0.3 million, respectively, which is included in research and development expenses on the condensed statement of operations and comprehensive loss. As of March 31, 2026, the Company accrued compensation expense of $0.1 million which is included in accrued expenses and other current liabilities on the condensed balance sheet. |